honors + affiliations
Member, Villanova Law Review
Member, Board of Directors, The Miquon School
- New Jersey
- U.S. Court of Appeals for the Third Circuit
- U.S. District Court for the District of New Jersey
- U.S. District Court for the Eastern District of Pennsylvania
Lisa C. Dykstra is a partner in Morgan Lewis's Litigation Practice and a member of the firm's White Collar Litigation and Government Investigations Practice, and the co-chair of the firm's Pharmaceutical Industry Practice. Ms. Dykstra handles a wide variety of government investigations, white collar matters, internal investigations, qui tam litigation, and class action litigation, including major representations in the pharmaceutical and technology industries.
Ms. Dykstra has experience litigating cases involving the False Claims Act, the Medicare Anti-Kickback Statute, the Medicaid Rebate Statute, and various federal and state civil and criminal fraud statutes. She has acted as lead counsel for major pharmaceutical companies and other entities in federal and state government investigations involving the marketing and pricing of products, marketing and promotional activities, FDA regulations, and class action litigation. Ms. Dykstra also has negotiated compliance agreements with the Department of Health and Human Services Office of Inspector General. In the computer industry, Ms. Dykstra represents a Fortune 50 California-based computer manufacturer in False Claims Act litigation, government investigations and consumer class-action lawsuits, and provides public sector contracting and compliance advice.
Ms. Dykstra is a former assistant U.S. attorney, having served as a prosecutor in the Criminal Division of the United States Attorney's Office for the District of New Jersey.
Ms. Dykstra has lectured on topics relating to compliance issues, white collar crime, and Civil False Claims Act litigation.
Ms. Dykstra co-authored an article in the January 2011 issue of BNA's Health Care Fraud Report, "OIG Exclusions and Individual Accountability: Key Developments for Executives in 2010 Will Have a Lasting Impact in 2011 and Beyond," analyzing recent legal and legislative developments related to the federal government's enforcement focus on healthcare executives and individual accountability in healthcare fraud and abuse matters.
In 2010 Ms. Dykstra served as a panelist at the PLI False Claims Litigation Seminar in New York on "Qui Tam Considerations: Handling of a False Claims Case with the Involvement of a Relator;" at the ACI Drug and Medical Device Litigation Conference in New York on "The Impact of Stepped Up Regulatory and Enforcement Activity on Products Claims and Litigation Strategy;" and at an ABA conference in Philadelphia on "The Government's Focus on Individual Executives and Employees."
In 2008 Ms. Dykstra presented at the ABA's 7th National Institute on Civil False Claims Act and Qui Tam Enforcement, Washington, D.C. as a panelist on "State Qui Tam Enforcement." In addition, Ms. Dykstra co-chaired ACI'S 3rd National Conference on Internal Investigations for the Drug & Device Industries, Philadelphia and served as a panelist on "Exercising Discretion from the Start: Structuring an Appropriate Situation-Specific and Company-Specific Investigation."
Ms. Dykstra also routinely participates in seminars and advises in-house counsel on the management of internal investigations, the creation and implementation of compliance programs, and decisions around indemnifying employees.
Ms. Dykstra is a member of the Criminal Justice Act Panel for the U.S. District Court for the Eastern District of Pennsylvania.
Ms. Dykstra is admitted to practice in Pennsylvania and New Jersey.
- Villanova University School of Law, 1992, J.D.
- New York University, 1989, B.A.